United Therapeutics (UTHR) Common Equity (2016 - 2025)
Historic Common Equity for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $6.6 billion.
- United Therapeutics' Common Equity rose 802.01% to $6.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 billion, marking a year-over-year increase of 802.01%. This contributed to the annual value of $6.4 billion for FY2024, which is 767.28% up from last year.
- United Therapeutics' Common Equity amounted to $6.6 billion in Q3 2025, which was up 802.01% from $7.2 billion recorded in Q2 2025.
- Over the past 5 years, United Therapeutics' Common Equity peaked at $7.2 billion during Q2 2025, and registered a low of $3.4 billion during Q1 2021.
- For the 5-year period, United Therapeutics' Common Equity averaged around $5.2 billion, with its median value being $5.3 billion (2024).
- In the last 5 years, United Therapeutics' Common Equity surged by 419.46% in 2024 and then soared by 2752.1% in 2025.
- Over the past 5 years, United Therapeutics' Common Equity (Quarter) stood at $4.0 billion in 2021, then rose by 21.16% to $4.8 billion in 2022, then increased by 24.77% to $6.0 billion in 2023, then rose by 7.67% to $6.4 billion in 2024, then rose by 2.27% to $6.6 billion in 2025.
- Its Common Equity was $6.6 billion in Q3 2025, compared to $7.2 billion in Q2 2025 and $6.8 billion in Q1 2025.